Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells $39,119.59 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) COO Daniel Lesueur sold 5,209 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the sale, the chief operating officer now owns 91,253 shares of the company's stock, valued at approximately $685,310.03. The trade was a 5.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Lesueur also recently made the following trade(s):

• On Tuesday, November 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $7.70, for a total transaction of $40,109.30.

Health Catalyst Price Performance

Shares of Health Catalyst stock traded down $0.47 on Friday, reaching $6.89. The stock had a trading volume of 477,428 shares, compared to its average volume of 547,021. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The company has a market cap of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The business's 50 day moving average is $7.79 and its two-hundred day moving average is $7.52.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million during the quarter, compared to analysts' expectations of $76.27 million. During the same period in the previous year, the company posted ($0.22) earnings per share. The company's quarterly revenue was up 3.5% compared to the same quarter last year. As a group, research analysts anticipate that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Quest Partners LLC bought a new position in shares of Health Catalyst in the third quarter worth approximately $34,000. Quarry LP increased its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company's stock worth $45,000 after purchasing an additional 2,610 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Health Catalyst in the third quarter worth approximately $59,000. Mackenzie Financial Corp bought a new position in shares of Health Catalyst in the second quarter worth approximately $70,000. Finally, Quadrature Capital Ltd bought a new position in Health Catalyst during the third quarter valued at approximately $84,000. 85.00% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HCAT has been the topic of a number of research analyst reports. Evercore ISI boosted their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th. KeyCorp raised shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price target on the stock in a report on Wednesday. Royal Bank of Canada boosted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a report on Thursday, November 7th. Stephens boosted their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a report on Thursday, November 14th. Finally, Citigroup cut their price target on shares of Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a report on Friday. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $11.45.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.